ES2109362T3 - Unas proteinas administrables oralmente y metodo para hacerlas. - Google Patents

Unas proteinas administrables oralmente y metodo para hacerlas.

Info

Publication number
ES2109362T3
ES2109362T3 ES92914240T ES92914240T ES2109362T3 ES 2109362 T3 ES2109362 T3 ES 2109362T3 ES 92914240 T ES92914240 T ES 92914240T ES 92914240 T ES92914240 T ES 92914240T ES 2109362 T3 ES2109362 T3 ES 2109362T3
Authority
ES
Spain
Prior art keywords
protein
therapeutic protein
stabilizing agent
administrable
coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92914240T
Other languages
English (en)
Inventor
Jacob G Michael
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Application granted granted Critical
Publication of ES2109362T3 publication Critical patent/ES2109362T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

SE PRESENTA UNA PROTEINA TERAPEUTICA QUE SE PUEDE ADMINISTRAR POR VIA ORAL A BASE DE COMBINAR LA PROTEINA TERAPEUTICA CON UN AGENTE ESTABILIZADOR EN UNA SOLUCION ACUOSA. SE REVISTE UNA PILDORA DE AZUCAR CON LA SOLUCION Y SE MICROENCAPSULA CON UNA COMPOSICION DE REVESTIMIENTO ENTERICA EMULSIONABLE EN AGUA. LAS MICROCAPSULAS SE ADMINISTRAN POR VIA ORAL. EL REVESTIMIENTO PROTEGE A LA PROTEINA A MEDIDA QUE ESTA PASA A TRAVES DEL ESTOMAGO. AL ALCANZAR LOS INTESTINOS DELGADOS, EL PH BASICO DE LOS JUGOS INTESTINALES DISOLVERA EL REVESTIMIENTO PERMITIENDO ASI LA LIBERACION DE LA PROTEINA. EL AGENTE ESTABILIZADOR PROTEGERA A LA PROTEINA TERAPEUTICA DURANTE EL PROCESO DE ENCAPSULACION E INHIBIRA LAS ENZIMAS PROTEOLITICAS DE LOS INTESTINOS DELGADOS LO QUE PERMITIRA QUE AL PROTEINA TERAPEUTICA ALCANCE EL TEJIDO LINFOIDE DE LOS INTESTINOS DELGADOS.
ES92914240T 1991-06-21 1992-06-11 Unas proteinas administrables oralmente y metodo para hacerlas. Expired - Lifetime ES2109362T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71916091A 1991-06-21 1991-06-21

Publications (1)

Publication Number Publication Date
ES2109362T3 true ES2109362T3 (es) 1998-01-16

Family

ID=24888975

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92914240T Expired - Lifetime ES2109362T3 (es) 1991-06-21 1992-06-11 Unas proteinas administrables oralmente y metodo para hacerlas.

Country Status (11)

Country Link
US (4) US5609871A (es)
EP (1) EP0590060B1 (es)
JP (1) JPH06508371A (es)
AT (1) ATE158180T1 (es)
AU (1) AU664561B2 (es)
CA (1) CA2110899C (es)
DE (1) DE69222306T2 (es)
DK (1) DK0590060T3 (es)
ES (1) ES2109362T3 (es)
GR (1) GR3025628T3 (es)
WO (1) WO1993000077A1 (es)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2109362T3 (es) * 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
US6083503A (en) * 1991-08-28 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
EP0603992B2 (en) † 1992-12-22 2000-12-06 University Of Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5551058A (en) * 1994-10-31 1996-08-27 Motorola, Inc. Method and system for intelligent cell selection using location data in cellular systems
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
US6605276B1 (en) * 1995-05-09 2003-08-12 University Of Medicine & Dentistry Of New Jersey Treatment of ulcerative colitis with tropomyosin isoforms and monoclonal antibodies to tropomyosin isoforms
US5789014A (en) * 1995-12-25 1998-08-04 Shin-Etsu Chemical Co., Ltd. Method of manufacturing a solid preparation coated with non-solvent coating
JP2000509146A (ja) * 1996-04-12 2000-07-18 オンコール，インコーポレーテッド 遅延クエンチングによりホルムアルデヒド固定を制御する方法および組成物
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6328967B1 (en) * 1998-03-12 2001-12-11 Allergenics, Inc. Delivery system to modulate immune response
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
DE19854749A1 (de) * 1998-11-27 2000-05-31 Privates Inst Bioserv Gmbh Verwendung von Kapseln, die eine oder mehrere antigene Substanzen enthalten, zur Prävention und/oder Behandlung von Autoimmunerkrankungen
BR9915771A (pt) * 1998-11-30 2001-12-26 Cytos Biotechnology Ag Apresentação molecular ordenada de antìgenos,processo de preparação e utilização
US6432448B1 (en) * 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
AU1267501A (en) * 1999-09-07 2001-04-10 Bioserv Ag Novel autogenous vaccines used to obtain an immune tolerance
US6500462B1 (en) * 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
WO2001051008A2 (en) * 2000-01-07 2001-07-19 University Of Cincinnati Selective activation of a th1 or th2 lymphocyte regulated immune response
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
ATE293988T1 (de) * 2000-02-08 2005-05-15 Allergan Inc Pharmazeutische zusammensetzungen mit botulinum toxin
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
EP2343317A1 (en) 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
US6932861B2 (en) * 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
BR0115585A (pt) 2000-11-28 2005-12-13 Fmc Corp Composições de revestimento de pronta liberação, endurecìvel, comestìvel, seca e, úmida, forma de dosagem sólida, e, método para revestir uma forma de dosagem sólida farmacêutica ou veterinária, confeito, semente, ração animal, fertilizante, comprimido de pesticida ou alimento
US20060040899A1 (en) * 2000-12-15 2006-02-23 Hassan Jomaa Medicaments containing bisphosphonic acids and derivatives thereof for preventing and treating diseases and allergies
JP2004535419A (ja) * 2001-06-05 2004-11-25 ユニバーシティ オブ シカゴ 免疫抑制を処置するためのメチルナルトレキソンの使用
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
EP1463527A4 (en) * 2001-10-04 2005-05-11 Protein Therapeutics Inc USE OF GAMMAGLOBULIN FOR THE TREATMENT OF IMMUNE-MEDIATED DISEASES
KR20040047915A (ko) * 2001-10-15 2004-06-05 룀 게엠베하 운트 콤파니 카게 활성제로서 펩타이드 또는 단백질을 함유하는 생약 형태를제조하기 위한 공중합체의 용도
PT1507554E (pt) 2002-05-10 2011-11-21 Agennix Inc Lactoferrina no tratamento de neoplasmas malignos e outras doenças hiperproliferativas
US20040043070A1 (en) * 2002-05-14 2004-03-04 Ayres James W. Hot melt coating by direct blending and coated substrates
US7977098B2 (en) 2002-05-31 2011-07-12 Children's Hospital Medical Center Antigenic binding patterns of norovirus to human histo-blood group antigens
AU2003273206B2 (en) * 2002-05-31 2009-08-20 Children's Hospital Medical Center Method, composition and kit for antigenic binding of Norwalk-Like viruses
DE60335997D1 (de) 2002-09-16 2011-03-24 Agennix Inc Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
JP4988201B2 (ja) 2002-10-16 2012-08-01 ユーロ−セルティーク エス．エイ． 細胞結合性ｃａ１２５／ｏ７７２ｐに結合する抗体およびその使用方法
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP2267032A3 (en) 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
KR20080113286A (ko) 2003-01-10 2008-12-29 아블린쓰 엔.브이. 폰 빌레브란트 인자(ｖＷＦ) 또는 콜라겐에 대한 낙타과로부터의 재조합 ＶＨＨ 단일 도메인 항체
CA2521420A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
ES2528669T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
WO2004091622A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
US20070141071A1 (en) * 2003-05-14 2007-06-21 Oregon State University Hot melt coating by direct blending and coated substrates
AU2004281080A1 (en) * 2003-10-16 2005-04-28 Stephen John Ralph Immunomodulating compositions and uses therefor
DE60334645D1 (de) 2003-11-07 2010-12-02 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
WO2006036278A2 (en) 2004-09-18 2006-04-06 University Of Maryland, Baltimore THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF
KR20070084170A (ko) * 2004-10-13 2007-08-24 아블린쓰 엔.브이. 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
WO2006078842A1 (en) * 2005-01-20 2006-07-27 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AU2006220682B2 (en) * 2005-03-07 2012-05-31 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006099175A2 (en) * 2005-03-11 2006-09-21 Euro-Celtique S.A. Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
CA2605652C (en) 2005-04-22 2016-05-24 Universite De Geneve Polylactide compositions and uses thereof
EP1885393A4 (en) 2005-05-18 2011-03-02 Childrens Hosp & Res Ct Oak METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST CHLAMYDIA INFECTIONS
PL1888640T3 (pl) 2005-05-18 2012-08-31 Ablynx Nv Ulepszone nanociała skierowane przeciwko czynnikowi martwicy nowotworów typu alfa
KR101414438B1 (ko) 2005-05-20 2014-07-10 아블린쓰 엔.브이. 폰 빌레브란트 인자에 대한 단일 도메인 ｖｈｈ 항체
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
CA2655331A1 (en) 2006-06-22 2007-12-27 Agennix Incorporated Lactoferrin as a radioprotective agent
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US20110152263A1 (en) * 2006-11-16 2011-06-23 Xi Jiang Composition and method for inhibiting norovirus infection
EP2111224B1 (en) 2007-01-12 2016-07-13 University of Maryland, Baltimore Targeting ncca-atp channel for organ protection following ischemic episode
EP2120580B1 (en) 2007-02-02 2017-12-27 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
PE20130480A1 (es) * 2007-03-29 2013-05-08 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
EP2565195B1 (en) * 2007-03-29 2015-05-06 Wyeth LLC Peripheral opioid receptor and antagonists and uses thereof
AU2008233133B2 (en) 2007-03-29 2014-03-27 Progenics Pharmaceuticals, Inc. Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof
KR101580938B1 (ko) 2007-06-01 2015-12-30 유니버시티 오브 매릴랜드, 발티모어 면역글로불린 불변영역 Ｆｃ 수용체 결합제
JP5322405B2 (ja) * 2007-06-07 2013-10-23 小林製薬株式会社 タンパク質含有組成物
EP2167107B1 (en) 2007-06-22 2016-12-14 University of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
US8685995B2 (en) * 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US20110250278A1 (en) 2008-07-01 2011-10-13 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
WO2010033560A2 (en) 2008-09-16 2010-03-25 University Of Maryland, Baltimore Sur1 inhibitors for therapy
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
JP2012524818A (ja) 2009-04-24 2012-10-18 バンダービルト ユニバーシティ 骨細胞機能および骨成長の抗ＴＧＦ−βによる誘導法
CN102612525A (zh) 2009-06-09 2012-07-25 儿童医院医疗中心 抗原-诺罗病毒p-结构域单体和二聚体，抗原-诺罗病毒p-粒子分子，及其制备和应用方法
WO2011011781A1 (en) 2009-07-24 2011-01-27 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
WO2011104352A1 (en) 2010-02-25 2011-09-01 Agennix Ag Oral lactoferrin in the treatment of severe sepsis
CA2902942C (en) 2010-07-28 2020-12-22 David S. Block Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
US10865445B2 (en) 2010-08-18 2020-12-15 Fred Hutchinson Cancer Research Center Methods for alleviating facioscapulohumeral dystrophy (FSHD) by N siRNA molecule inhibiting the expression of DUX4-FL
BR112013006088B1 (pt) 2010-09-15 2022-06-14 Randall J Mrsny Construto de entrega isolado, e, composição farmacêutica
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
WO2012053976A1 (en) 2010-10-18 2012-04-26 Agency For Science, Technology And Research Use of exosomes to promote or enhance hair growth
WO2012070971A1 (ru) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Косметологическая и фармацевтическая композиция для омоложения и восстанов- ления кожи, в том числе после хирургических операций
EP2734634B1 (en) 2011-07-22 2019-08-21 The University of Chicago Igf-1 for use in the treatment of migraine
US9655905B2 (en) 2011-09-14 2017-05-23 King Abdullah University Of Science And Technology Treatment of sickle cell disease
EP2758519B1 (en) 2011-09-21 2017-03-29 King Abdullah University Of Science And Technology Didemnin biosynthetic gene cluster in tistrella mobilis
AR092821A1 (es) 2012-04-20 2015-05-06 Sucampo Ag Conjugado de derivado de acido graso-polimero
WO2014160339A1 (en) 2013-03-13 2014-10-02 Board Of Regents, The University Of Texas System Compounds for treating inflammatory and hyperproliferative diseases
US9321803B2 (en) 2013-07-12 2016-04-26 Children's Hospital Medical Center Compositions and methods for inhibiting norovirus infection
JP6667437B2 (ja) 2013-12-02 2020-03-18 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 最適な体重及び血糖を維持するための新規ポリペプチドホルモンの同定
EP3107568B1 (en) * 2014-02-20 2024-03-27 Vaxart, Inc. Formulations for small intestinal delivery
US20170051354A1 (en) * 2014-04-28 2017-02-23 Sigma-Aldrich Co. Llc Epigenetic modification of mammalian genomes using targeted endonucleases
ES2900328T3 (es) 2014-05-07 2022-03-16 Applied Molecular Transport Inc Moléculas de fusión derivadas de toxina Cholix para la administración oral de carga biológicamente activa
US10278986B2 (en) 2014-08-14 2019-05-07 The Regents Of The University Of Colorado, A Body Corporate Antibody-siRNA conjugates and uses therefor
EP3191131A4 (en) 2014-08-21 2018-09-05 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
EP3718404A1 (en) 2014-10-17 2020-10-07 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progession
WO2016073184A1 (en) 2014-11-04 2016-05-12 Dana Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
KR101708200B1 (ko) 2015-03-24 2017-03-08 아우토리브 디벨롭먼트 아베 차량용 커튼 에어백
EP3285792B1 (en) 2015-04-20 2020-11-04 The Board of Regents of The University of Texas System Clec11a is a bone growth agent
WO2016200951A1 (en) * 2015-06-12 2016-12-15 Vaxart, Inc. Formulations for small intestinal delivery of rsv and norovirus antigens
US10962551B2 (en) 2015-06-17 2021-03-30 The Johns Hopkins University TDP-43 in degenerative disease
PT3325011T (pt) 2015-07-24 2021-01-27 Gliknik Inc Proteínas de fusão de fragmentos de proteína humana para criar composições de fc de imunoglobulina multimerizadas ordenadamente com ligação a complemento melhorada
NZ738950A (en) 2015-08-07 2023-03-31 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
EA034582B1 (ru) 2015-08-07 2020-02-21 АЭлЭкс ОНКОЛОДЖИ ИНК. Конструкции варианта sirp-альфа и их применение
US10695322B2 (en) 2016-01-29 2020-06-30 The Johns Hopkins University Inhibitors of bacterial growth
US11040025B2 (en) 2016-02-17 2021-06-22 The Johns Hopkins University Oxazolidinone for treatment of infections with Mycobacterium tuberculosis
WO2017147370A1 (en) 2016-02-24 2017-08-31 The Johns Hopkins University Novel antiviral proteins and their uses in therapeutic methods
US10888549B2 (en) 2016-03-07 2021-01-12 The Johns Hopkins University Pharmaceutical agents targeting cancer stem cells
CN109790545A (zh) 2016-03-10 2019-05-21 约翰·霍普金斯大学 产生不含聚集物的单体白喉毒素融合蛋白的方法和治疗用途
US11203626B2 (en) 2016-03-10 2021-12-21 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
CN109414417A (zh) 2016-03-17 2019-03-01 约翰·霍普金斯大学 通过paris的法尼基化预防或治疗帕金森症的方法
WO2017173055A1 (en) 2016-03-30 2017-10-05 The Johns Hopkins University Olfr90 specificity and methods of detection
JP7224917B2 (ja) 2016-03-31 2023-02-20 ソリッソ ファーマシューティカルズ，インク． 組成物
WO2017189483A1 (en) 2016-04-25 2017-11-02 The Johns Hopkins University Znt8 assays for drug development and pharmaceutical compositions
SG11201900427PA (en) 2016-07-22 2019-02-27 Gliknik Inc Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding
EP3295956A1 (en) 2016-09-20 2018-03-21 Biomay Ag Polypeptide construct comprising fragments of allergens
US11149275B2 (en) 2016-10-10 2021-10-19 The Johns Hopkins University Device and method to treat esophageal disorders
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
EP3551647A4 (en) 2016-12-09 2021-01-13 Gliknik Inc. MANUFACTURING OPTIMIZATION OF GL-2045, MULTIMERIZING STRADOMER
US10434089B2 (en) 2017-01-25 2019-10-08 The Johns Hopkins University Avibactam and carbapenems antibacterial agents
JP2020515531A (ja) 2017-03-28 2020-05-28 チルドレンズ ホスピタル メディカル センター ノロウイルスｓ粒子ベースのワクチンならびにその作製および使用方法
US11892457B2 (en) 2017-07-12 2024-02-06 The Johns Hopkins University Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
EP3459528B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
WO2019118527A1 (en) 2017-12-14 2019-06-20 The Johns Hopkins University Novel anti-fungal inhibitors
SI3762009T1 (sl) 2018-03-08 2023-03-31 Applied Molecular Transport Inc. Iz toksinov izpeljani dostavni konstrukti za peroralno dostavo
PT3762009T (pt) 2018-03-08 2022-08-22 Applied Molecular Transport Inc Construções de administração derivadas de toxinas para administração oral
US20220096600A1 (en) 2019-02-07 2022-03-31 Baylor College Of Medicine Periosteal skeletal stem cells in bone repair
US11717506B2 (en) 2019-05-07 2023-08-08 The Johns Hopkins University Neuroprotective compounds for amyotrophic lateral sclerosis
SG11202112733XA (en) 2019-05-31 2021-12-30 Alx Oncology Inc Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
US20230056445A1 (en) 2019-06-21 2023-02-23 Sorriso Pharmaceuticals, Inc. Polypeptides
WO2020254826A1 (en) 2019-06-21 2020-12-24 Vhsquared Limited Polypeptides
CN114599665A (zh) 2019-08-16 2022-06-07 应用分子转运公司 组合物、制剂及白细胞介素产生和纯化

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
LU76538A1 (es) * 1977-01-07 1978-09-18
US4469677A (en) * 1980-02-19 1984-09-04 Michael J Gabriel Polypeptide active immunosuppressant fraction
JPS5855125B2 (ja) * 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5230888A (en) * 1982-05-06 1993-07-27 Massachusetts Institute Of Technology Production of neutralizing antibodies by polypeptide VP1 of enteroviruses and by oligopeptide fragments of polypeptide VP1
US4507276A (en) * 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
SE8303401D0 (sv) * 1983-06-15 1983-06-15 Pharmacia Ab Beredning och dess anvendning
US4704295A (en) * 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
DE3431861A1 (de) * 1984-08-30 1986-03-13 Troponwerke GmbH & Co KG, 5000 Köln Pellet-zubereitung
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
EP0192321A3 (en) * 1985-01-19 1987-09-02 Beecham Group Plc Enteric coated allergen pharmaceutical composition
CH663900A5 (de) * 1985-05-06 1988-01-29 Cernitin Sa Pharmazeutisches praeparat zur prophylaktischen behandlung von allergien und verfahren zur herstellung dieses praeparates.
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
US4820627A (en) * 1986-03-24 1989-04-11 Em Diagnostic Systems, Inc. Method of preparing particles suitable for tabletting into diagnostic reagents
JPH0759496B2 (ja) * 1986-03-25 1995-06-28 ロ−ト製薬株式会社 歯周病治療剤
US5019384A (en) * 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
JP2593501B2 (ja) * 1986-08-28 1997-03-26 コーテクス・リミテッド 動物成長促進剤
FR2609895B1 (fr) * 1987-01-28 1991-06-28 Bruttmann Georges Nouvelles formes galeniques d'allergenes pour administration par voie per- et sub-linguale
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPS6417A (en) * 1987-02-20 1989-01-05 Shikoku Chem Corp Chemotherapeutic agent composition
US4874613A (en) * 1987-03-06 1989-10-17 Baker Cummins Pharmaceuticals, Inc. Taste concealing pharmaceutical dosage unit
US4946945A (en) * 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5049390A (en) * 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US5236713A (en) * 1987-10-21 1993-08-17 Teikoku Seiyaku Kabushiki Kaisha Preparation for intermittently releasing active agent applicable to oral cavity
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
ES2042292T3 (es) * 1989-03-17 1993-12-01 Pitman-Moore, Inc. Dispositivo de administracion de proteinas macromoleculares por liberacion controlada.
CA2020654A1 (en) 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
CA2092905C (en) * 1990-10-15 2002-01-08 Howard L. Weiner Treatment of autoimmune diseases by oral administration of autoantigens
JPH04230625A (ja) * 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法
ES2109362T3 (es) * 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
EP0603992B2 (en) * 1992-12-22 2000-12-06 University Of Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins

Also Published As

Publication number Publication date
US5783193A (en) 1998-07-21
CA2110899C (en) 2006-08-08
EP0590060A1 (en) 1994-04-06
US5609871A (en) 1997-03-11
US6174529B1 (en) 2001-01-16
EP0590060B1 (en) 1997-09-17
US5629001A (en) 1997-05-13
AU664561B2 (en) 1995-11-23
DK0590060T3 (da) 1998-05-11
WO1993000077A1 (en) 1993-01-07
GR3025628T3 (en) 1998-03-31
ATE158180T1 (de) 1997-10-15
DE69222306D1 (de) 1997-10-23
CA2110899A1 (en) 1993-01-07
EP0590060A4 (en) 1994-05-25
AU2249692A (en) 1993-01-25
DE69222306T2 (de) 1998-04-09
JPH06508371A (ja) 1994-09-22

Similar Documents

Publication Publication Date Title
ES2109362T3 (es) Unas proteinas administrables oralmente y metodo para hacerlas.
DK0603992T4 (da) Oral indgivelse af immunologisk aktive biomolekyler og andre terapeutiske proteiner
DE69730991D1 (de) Alginsaure enthaltende enterischer ueberzug fuer eine orale zubereitung
NO882732D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
SE8001736L (sv) Indolerivat med terapeutisk verkan jemte sett for deras framstellning
NO995236D0 (no) Nerve-vekstfaktor som vaksine-adjuvant
SE8505569D0 (sv) Enteralt preparat
JP2002326953A (ja) 経粘膜法により吸収されるワクチン
IT1237475B (it) Allergeni modificati chimicamente e procedimento per la loro preparazione
ISSHIKI Effect of lactobacilli in the diet on the concentration of nitrogenous compounds and minerals in blood of chickens
FR2618439B1 (fr) Sequences d'amino-acides reproduisant au moins en partie la sequence des lectines animales et humaines, leurs procedes d'obtention, leurs applications diagnostiques et therapeutiques
RU1808324C (ru) Способ профилактики и лечени казеинобезоарной болезни новорожденных гн т
RU2000104571A (ru) Способ коррекции иммунной недостаточности при желудочно-кишечных заболеваниях поросят
O'Brien et al. Enterotoxic diseases due to Salmonella and Shigella.
ES444286A1 (es) Perfeccionamientos en la obtencion de composiciones suspen- dibles en agua de 1,3-bis((-p-clorobencilideno
EA199900044A1 (ru) Способ получения витаминного препарата и способ получения водорастворимого препарата
FR2148211A1 (en) Human milk substitute - prepd from whey and milk protein materials pptd at isoelectric point
RU93056259A (ru) Средство для лечения диспепсии телят
CA861444A (en) Poultry flavor comprising amino acids, sugars, vegetable protein hydrolysate and 5'-ribonucleotides
RU2000126729A (ru) Способ лечения язвенной болезни желудка и двенадцатиперстной кишки
RU94001136A (ru) Белковый гидролизат "субамин"
KR20010081232A (ko) 산도에 민감한 중합체를 이용한 달걀 면역 항체의캡슐화방법
RU97117569A (ru) Гастроветин
RU93056258A (ru) Способ лечения диспепсии телят
RU93057215A (ru) Способ стимуляции воспроизводительной способности пушных зверей и сохранения молодняка

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 590060

Country of ref document: ES